Surrogate endpoints, part 2 further developments /

احصل على النص الكامل
Series

Patient heterogeneity in dose-finding trials part 1, methods for 2 groups/

احصل على النص الكامل
Series

Patient heterogeneity in dose-finding trials part 2, more than 2 groups /

احصل على النص الكامل
Series

Design and conduct of non-inferiority trials

احصل على النص الكامل
Series (Risk of bias in randomized clinical trials)
Series (Design and analysis of randomized clinical trials)

Overview of clinical pharmacology in cancer part 2 of 2 /

احصل على النص الكامل
Series

Case studies of adaptive early phase trials

احصل على النص الكامل
Series

Ligand-based drug design

احصل على النص الكامل

Structure-based drug design

احصل على النص الكامل

General introduction to non-clinical toxicity testing of pharmaceuticals

احصل على النص الكامل
Series

Arylamine N-acetyltransferases part 2 of 3 /

احصل على النص الكامل
Series

Arylamine N-acetyltransferases part 3 of 3 /

احصل على النص الكامل
Series

Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism Part II. Internal medicine /

احصل على النص الكامل
Series

Arylamine N-acetyltransferases part 1 of 3 /

احصل على النص الكامل
Series

The dynamic interactions between cellular-molecular physiology and the environment part 4, Future directions in cellular-molecular evolutionary biology /

احصل على النص الكامل
Series

Pharmacogenomics in cancer therapy

احصل على النص الكامل
Series

Rules and filters and their impact on success in chemical biology and drug discovery

احصل على النص الكامل
Series

Key drug discovery challenges in cardiovascular medicine

احصل على النص الكامل
Series (Genetics of cardiovascular disease)
Series (Small molecule drug discovery)

Fragment-based lead discovery

احصل على النص الكامل
Series

Virtual screening

احصل على النص الكامل
Series

A structured approach for pharmaceutical pre-marketing safety surveillance

احصل على النص الكامل